General Anesthesia Drugs Market Size, Share, Growth Analysis, By Route Of Administration(Inhalational (Sevoflurane, Desflurane, Isoflurane, Nitrous Oxide)), By End User(Hospitals, Ambulatory Surgery Centers), By Region - Industry Forecast 2024-2031

The global market for general anaesthesia drugs is extremely fragmented, with multiple rivals in the development of general anaesthetic drugs. These firms are employing techniques such as mergers and acquisitions, partnerships and collaborations, and new product releases to match consumer demand and increase their client base. Furthermore, firms operating in the market are obtaining favourable findings for the potential effect of chemicals such as general anaesthesia, which might raise market growth even further. For instance, In June 2021, PAION AG, a speciality pharmaceutical firm, received favourable findings in the European Phase III trial for Remimazolam. It is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic that is licenced for procedural sedation in the United States, Europe, and China, as well as general anaesthesia in South Korea and Japan. By the end of 2021, PAION AG intends to file an extension modification to the Marketing Authorization for remimazolam as general anaesthesia. As a result, the company's actions will broaden the market perspective in numerous areas, adding to market growth.

General Anesthesia Drugs Market Top Player's Company Profiles

• AbbVie Inc.
• AstraZeneca
• Fresenius SE & Co. KGaA
• Hikma Pharmaceuticals PLC
• Hospira Inc. (Pfizer Inc.)
• Jiangsu Nhwa Pharmaceutical Co. Ltd.
• Merck & Co. Inc.
• Mylan N.V.
• Novartis AG
• Piramal Healthcare
• Roche Holding AG
• Teva Pharmaceuticals
• B. Braun Melsungen AG
• Baxter International Inc.
• Cardinal Health Inc.
• Maruishi Pharmaceutical Co. Ltd.
• Nippon Zenyaku Kogyo Co. Ltd.
• Shandong Baolai-Leelai Bio-Tech. Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Wockhardt Ltd.

General Anesthesia Drugs Market Recent Development

• In February 2022, Sedana Medical AB has launched Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) will be approved by the European DCP In addition, in July 2021. the product has been granted national approval in 14 nations. Additional marketing clearance applications were submitted in the same year, and the business expects to gain national approvals in Italy, Poland, Switzerland, and the United Kingdom in 2022.
• In January 2022, Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratoires Théa SAS (Théa). Théa will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic intended for ocular surface anaesthetic during ophthalmologic operations, as a result of the strategic move.